Key result
DES healing in cancer patients matches non-cancer controls, while advanced cancer links to ~250% higher mortality.
Why the study?
Cancer treatments may delay stent healing and elevate stent thrombosis risk, especially if dual antiplatelet therapy is stopped early for oncology care.
Does drug-eluting stent placement in cancer patients result in similar stent healing parameters compared to non-cancer patients?
Cohort (n=67)
No
Does drug-eluting stent placement in cancer patients result in similar stent healing parameters compared to non-cancer patients?
Hazard Ratio: 3.5 (95% CI 1.18–10.42)
p-value: p=0.024
Stent healing of contemporary DES in cancer patients appears similar to non-cancer patients, suggesting that early DAPT discontinuation may be safe to facilitate timely cancer therapies.
Comparable DES healing in cancer patients; leaves open abbreviated DAPT feasibility pending prospective trials.
Objective: This study assessed stent healing patterns and cardiovascular outcomes by optical coherence tomography (OCT) in cancer patients after drug-eluting stent (DES) placement. Background: Cancer treatment, owing to its cytotoxic and antiproliferative effects, could delay stent healing and increase stent thrombosis risk, especially when dual antiplatelet therapy (DAPT) is discontinued early for oncological treatment. OCT can assess stent endothelialization and other healing parameters, which may provide clinical guidance in these challenging scenarios. Methods: This single-center retrospective study enrolled all cancer patients who underwent OCT for assessment of vascular healing patterns after prior DES placement from November 2009 to November 2018. Primary study endpoints were stent healing parameters, including stent coverage, apposition, degree of expansion, neointimal hyperplasia heterogeneity, in-stent restenosis, stent thrombosis, and overall survival (OS). Results: A total of 67 patients were included in this study. Mean time between DES placement and OCT evaluation was 154 ± 82 days. Stent healing matched published values for DES in non-cancer patients (P ≥ 0.063). At 1 year, the OS was 86% (95% confidence interval [CI]: 78–96%) with 0% incidence of acute coronary syndrome. Advanced cancers and active chemotherapies were associated with inferior OS (P = 0.024, hazard ratio [HR]: 3.50, 95% CI: 1.18–10.42 and P = 0.026, HR: 2.65, 95% CI: 1.13–6.22, respectively), while stent healing parameters were unassociated with OS. Forty-one patients (61%) had DAPT duration ≤6 months. Conclusions: Stent healing of contemporary DES appears similar in cancer and non-cancer patients. Cardiovascular risk of cancer patients after DES placement can be managed to facilitate timely cancer therapies, as the underlying malignancy and active chemotherapy ultimately determine survival.
No takes yet. Share an insight, caveat, or question.
Aziz et al. (2021) conducted a cohort in Cancer with coronary artery disease (n=67). Drug-eluting stent placement vs. Non-cancer patients (historical controls) / Early-stage cancer was evaluated on Overall survival (advanced vs early-stage cancer) (HR 3.50, 95% CI 1.18-10.42, p=0.024). Stent healing of contemporary drug-eluting stents in cancer patients was similar to non-cancer patients, while advanced cancer was significantly associated with inferior overall survival (HR 3.50).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: